Tongji Hospital in China to Equip New Proton Therapy Center with MEVION S250i Proton Therapy System®

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System® in Wuhan, China.

The system at Tongji Hospital will feature Mevion’s industry-leading HYPERSCAN® Pencil Beam Scanning (PBS) technology, coupled with the industry’s only proton multi-leaf collimator, the Adaptive Aperture®. This powerful duo provides faster and more precise targeted dose delivery to tumors thus further minimizing the damage to surrounding healthy tissue and organs at risk. The system also integrates a diagnostic CT imaging system and a surface tracking system for high precision patient positioning and intra-fraction motion management.

Founded in 1900 and listed as the 6th top hospital in Fudan’s 2020 China Hospital Ranking, Tongji Hospital provides over 6 million annual outpatient visits. The contract for the new proton therapy center was completed in late 2021, and construction of the new 135,000 square-foot proton therapy center at Tongji Hospital’s Optics Valley campus is expected to be completed by December 2022. The installation of the MEVION S250i is planned to commence in July.

Tongji Hospital will build a second proton vault simultaneously, making it China’s first proton center applying the One Plus One multi-system installation approach. This allows Tongji Hospital the flexibility to add a second system in the future to correspond to the growth of patient volume and clinical expertise. This staged installation significantly reduces the financial burden at the start of the clinical proton therapy program and minimizes the risk of technology obsolescence.

“Mevion is proud to partner with the distinguished Tongji Hospital to provide accessible proton therapy to their patients,” said Tina Yu, Ph.D., chief executive officer and president of Mevion. “Mevion strongly believes health care systems will greatly benefit from expanding their proton centers at their optimal pace with the most advanced technology to best serve their patients.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.